Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML
Clinical trial NCT07605949 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07605949
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-07-01
- Primary completion
- 2028-07-01
- Enrollment
- 88
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.